117 related articles for article (PubMed ID: 36529453)
1. SARS-CoV-2 Omicron BA.5 Infections in Vaccinated Persons, Rural Uganda.
Mugisha J; Mpairwe B; Newton R; Cotten M; Phan MVT
Emerg Infect Dis; 2023 Jan; 29(1):224-226. PubMed ID: 36529453
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May-June 2021.
Harris JR; Owusu D; O'Laughlin K; Cohen AL; Ben Hamida A; Patel JC; Freeman MM; Nsibambi T; Nieves R; Marston BJ; Wasike S; Galbraith JS; Boore AL; Nelson LJ; Guagliardo SAJ; Klena JD; Patel K; Ma M
Emerg Infect Dis; 2022 Jun; 28(6):1279-1280. PubMed ID: 35470796
[TBL] [Abstract][Full Text] [Related]
3. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
[TBL] [Abstract][Full Text] [Related]
4. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
5. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
7. Rapid Replacement of SARS-CoV-2 Variants by Delta and Subsequent Arrival of Omicron, Uganda, 2021.
Bbosa N; Ssemwanga D; Namagembe H; Kiiza R; Kiconco J; Kayiwa J; Lutalo T; Lutwama J; Ssekagiri A; Ssewanyana I; Nabadda S; Kyobe-Bbosa H; Giandhari J; Pillay S; Ramphal U; Ramphal Y; Naidoo Y; Tshiabuila D; Tegally H; San EJ; Wilkinson E; de Oliveira T; Kaleebu P
Emerg Infect Dis; 2022 May; 28(5):1021-1025. PubMed ID: 35320700
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA.
Keyel AC; Russell A; Plitnick J; Rowlands JV; Lamson DM; Rosenberg E; St George K
Emerg Infect Dis; 2022 Oct; 28(10):1990-1998. PubMed ID: 36048774
[TBL] [Abstract][Full Text] [Related]
9. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.
Esper FP; Adhikari TM; Tu ZJ; Cheng YW; El-Haddad K; Farkas DH; Bosler D; Rhoads D; Procop GW; Ko JS; Jehi L; Li J; Rubin BP
J Infect Dis; 2023 Feb; 227(3):344-352. PubMed ID: 36214810
[TBL] [Abstract][Full Text] [Related]
10. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
11. Emergence and Persistent Dominance of SARS-CoV-2 Omicron BA.2.3.7 Variant, Taiwan.
Shao PL; Tu HC; Gong YN; Shu HY; Kirby R; Hsu LY; Yeo HY; Kuo HY; Huang YC; Lin YF; Weng HY; Wu YL; Chen CC; Chen TW; Lee KM; Huang CG; Shih SR; Chen WJ; Wu CC; Yu CJ; Tsai SF
Emerg Infect Dis; 2023 Apr; 29(4):792-796. PubMed ID: 36918378
[TBL] [Abstract][Full Text] [Related]
12. Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark.
Lyngse FP; Kirkeby CT; Denwood M; Christiansen LE; Mølbak K; Møller CH; Skov RL; Krause TG; Rasmussen M; Sieber RN; Johannesen TB; Lillebaek T; Fonager J; Fomsgaard A; Møller FT; Stegger M; Overvad M; Spiess K; Mortensen LH
Nat Commun; 2022 Sep; 13(1):5760. PubMed ID: 36180438
[TBL] [Abstract][Full Text] [Related]
13. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
14. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
[TBL] [Abstract][Full Text] [Related]
15. Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022.
Sofonea MT; Roquebert B; Foulongne V; Morquin D; Verdurme L; Trombert-Paolantoni S; Roussel M; Bonetti JC; Zerah J; Haim-Boukobza S; Alizon S
Emerg Infect Dis; 2022 Jul; 28(7):1355-1365. PubMed ID: 35642476
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
17. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
18. Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USA.
Seid AG; Yirko T; Sayeed S; Plipat N
Emerg Infect Dis; 2022 Sep; 28(9):1911-1913. PubMed ID: 35914519
[TBL] [Abstract][Full Text] [Related]
19. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
20. University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022.
Fowle N; Garrett B; Floyd OL; Collins J; Krasnow AD; Islas M; Holland SC; Smith MF; Lim ES; Jarrett NM; Scott SE
Emerg Infect Dis; 2022 Jul; 28(7):1520-1522. PubMed ID: 35654405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
